Pulmonary Arterial Hypertension Treatment Market Trend, Share, Growth, Demand, Size and Forecast 2032

Pulmonary Arterial Hypertension Treatment Industry Prospective:

The global pulmonary arterial hypertension treatment market size was worth around USD 7.88 billion in 2023 and is predicted to grow to around USD 12.76 billion by 2032 with a compound annual growth rate (CAGR) of roughly 5.5% between 2024 and 2032.

Request Free Sample  

Pulmonary Arterial Hypertension Treatment Market: Overview

As pulmonary hypertension—defined as a mean pulmonary arterial pressure of more than 25 mm Hg at rest or more than 30 mm Hg during exercise—a persistent and protracted elevation in pulmonary vascular resistance is a typical feature that might eventually lead to right ventricular failure. It has the potential to be fatal if left untreated. Pneumatic hypertension therapy success rates are based on the underlying reason and its effect on the cardiovascular system. These vary based on the etiology. Novel therapeutic compounds, such as prostacyclin and others entering clinical investigation, may make specialized treatments for many previously incurable conditions conceivable.

Key Insights

• As per the analysis shared by our research analyst, the global pulmonary arterial hypertension treatment market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2024-2032).
• In terms of revenue, the global pulmonary arterial hypertension treatment market size was valued at around USD 7.88 billion in 2023 and is projected to reach USD 12.76 billion by 2032.
• The growing geriatric population is expected to drive the pulmonary arterial hypertension treatment market growth over the forecast period.
• Based on the drug class, the prostacyclin and prostacyclin analogs segment is expected to dominate the market during the forecast period.
• Based on the type, the branded segment is expected to hold a prominent market share over the projected period.
• Based on region, North America is expected to dominate the market during the forecast period.

Request Free Sample

Pulmonary Arterial Hypertension Treatment Market: Growth Drivers

Rising geriatric population drives market growth

The pulmonary arterial hypertension (PAH) treatment market is growing due to a substantial number of people over sixty. People's immune systems may deteriorate with age, increasing their vulnerability to PAH and related illnesses. While PAH usually manifests at 45 years of age, people beyond 60 are increasingly being diagnosed with it. As they strive to receive the finest care available to extend their lives and improve their quality of life, this aging demographic is a significant target market for PAH treatments. This group will probably expect better treatments and management choices due to advancements in medical technology and improved access to care. The quality of life and healthcare outcomes for those with PAH in their older years will be enhanced by identifying this trend and attending to the unique needs of this population.

Pulmonary Arterial Hypertension Treatment Market: Restraints

Side effects of the drug hinder market growth

The adverse effects of the medication used to treat PAH are one of the constraints for the restricted expansion of the pulmonary arterial hypertension treatment industry. For instance, in pulmonary arterial hypertension, sotatercept lowers death and clinical deterioration by 84%, according to the American College of Cardiology. Researchers randomly assigned 323 patients with WHO group I and WHO functional class II or III PAH receiving background PAH treatment to sotatercept (Accutane) in phase 3 of the randomized, double-blind, placebo-controlled STELLAR study. Every three weeks, the initial dose of 0.3 mg/kg was increased to 0.7 mg/kg.

Pulmonary Arterial Hypertension Treatment Market: Opportunities

Increasing drug approval offers a lucrative opportunity for market growth

Increasing drug approval is expected to offer a lucrative opportunity for pulmonary arterial hypertension treatment market growth during the forecast period. For instance, in March 2024, the FDA approved sotatercept-csrk (U.S. Brand Name: WINREVAIRTM, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to improve WHO functional class (FC), increase exercise capacity, and lower the risk of clinical worsening events. Merck, which is known as MSD outside of the United States and Canada, made this announcement. Earlier, the FDA designated WINREVAIR as a breakthrough therapy. As the first FDA-approved activin signaling inhibitor medication for PAH, WINREVAIR represents a novel class of treatment that modulates pro- and anti-proliferative signaling to control vascular cell proliferation, the underlying cause of PAH.

Pulmonary Arterial Hypertension Treatment Market: Challenges

High cost and limited awareness pose a major challenge to market expansion

PAH medicines can be highly expensive, especially when it comes to new medications and combination therapies. Many patients may find their access restricted by this high cost, particularly in low- and middle-income nations. The total financial strain on healthcare systems might be high, which restricts the amount of funding available for PAH therapies. Furthermore, a lack of knowledge among the public and healthcare practitioners means that PAH is still underdiagnosed in many places. Early symptoms are frequently vague, which causes delays in diagnosis. Many places lack access to facilities and specialists in PAH, which makes it difficult to diagnose the disease early and accurately and to treat it effectively.

Pulmonary Arterial Hypertension Treatment Market: Segmentation

The global pulmonary arterial hypertension treatment industry is segmented based on drug class, type, route of administration, and region.

Based on the drug class, the global pulmonary arterial hypertension treatment market is bifurcated into Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors and SGC Stimulators. The Prostacyclin and Prostacyclin Analogs segment is expected to dominate the market during the forecast period. When treating pulmonary arterial hypertension (PAH), prostacyclin and its analogs are an essential family of medications. These drugs function by widening the pulmonary arteries and preventing platelet aggregation, which lowers lung blood pressure and enhances symptoms and survival rates in PAH sufferers. Subcutaneous, intravenous, and inhaled formulations are just a few examples of how medication delivery system innovations have extended the market and enhanced patient compliance. These developments improve the ease of treatment and may increase its efficacy. Further driving the market's expansion has been the approval of novel prostacyclin analogs and combination treatments. For instance, treprostinil, which is sold under numerous brand names, is available in different formulations to meet the demands of diverse patient populations.

Based on the type, the global pulmonary arterial hypertension treatment industry is bifurcated into generic and branded. The branded segment is expected to hold a prominent market share over the projected period. A robust pipeline, a growing number of product approvals, and significant investments made by market participants account for the majority of the branded industry. Moreover, a growing number of product launches is anticipated to support category growth throughout the projection period. For instance, United Therapeutics Corporation got FDA approval in June 2022 for the use of its Tyvaso DPI powder in the treatment of pulmonary arterial hypertension.

Based on the route of administration, the global pulmonary arterial hypertension treatment market is bifurcated into intravenous/subcutaneous, oral, and inhalational.

Pulmonary Arterial Hypertension Treatment Market: Report Scope

Pulmonary Arterial Hypertension Treatment Market: Regional Analysis

North America is expected to dominate the market during the forecast period

North America is expected to dominate the pulmonary arterial hypertension treatment market during the forecast period. The expansion has been significantly influenced by the North American region, specifically the United States. North America is becoming a major player in the field of PAH due to several factors that have led to its growth. The expansion of the industry has been greatly aided by North American reimbursement systems for PAH medicines. By lowering the cost of PAH therapies, these initiatives assist patients and healthcare professionals have more access to them. Reimbursement methods guarantee that patients can obtain the therapies they require without significant financial barriers, improving patient adherence and overall health results. Thereby, driving the market expansion in the region.

Pulmonary Arterial Hypertension Treatment Market: Competitive Analysis

The global pulmonary arterial hypertension treatment market is dominated by players like:

• Pfizer Inc.
• Arena Pharmaceuticals Inc.
• Actelion Pharmaceuticals Ltd (Johnson & Johnson)
• AstraZeneca PLC
• Bayer Aktiengesellschaft
• Daiichi Sankyo Company Limited
• Gilead Science Inc.
• GlaxoSmithKline PLC
• Merck KGaA
• Novartis International AG
• United Therapeutics Corporation

The global pulmonary arterial hypertension treatment market is segmented as follows:

By Drug Class

• Prostacyclin and Prostacyclin Analogs
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• SGC Stimulators

By Type

• Generics
• Branded

By Route of Administration

• Intravenous/Subcutaneous
• Oral
• Inhalational

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa